Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Sureda

Showing results (311-320 of 335) with videos related to

Pageof 34
Sort By:
Blood|February 19, 2025
Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMTCarmelo Gurnari, Marie Robin, Lionel Adès, et al.
The New England Journal of Medicine|December 12, 2023
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple MyelomaPieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, et al.
Eclinicalmedicine|January 22, 2026
HCT Frailty Scale (HCT-FS) for assessing frailty in adult candidates for allogeneic haematopoietic cell transplantation: an international prospective, observational cohort studyMaría Queralt Salas, Tommy Alfaro Moya, Ivan Pasic, et al.
Bone Marrow Transplantation|March 15, 2023
Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART eraAlberto Mussetti, Leyre Bento, Mariana Bastos-Oreiro, et al.
Nature Communications|September 20, 2023
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistanceCirino Botta, Cristina Perez, Marta Larrayoz, et al.
Future Oncology (London, England)|September 17, 2024
A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myelomaPieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, et al.
Therapeutic Advances in Medical Oncology|September 9, 2021
Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspectiveGehan Soosaipillai, Anjui Wu, Gino M Dettorre, et al.
Experimental Hematology & Oncology|September 1, 2020
Risk factors and outcome of COVID-19 in patients with hematological malignanciesJosé Luis Piñana, Rodrigo Martino, Irene García-García, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 20, 2014
Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphomaBaldeep Wirk, Timothy S Fenske, Mehdi Hamadani, et al.
American Journal of Hematology|August 19, 2024
Global characteristics and outcomes of autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma: A study of the worldwide network for blood and marrow transplantation (WBMT)Laurent Garderet, Luuk Gras, Linda Koster, et al.
Pageof 34

Showing results (311-320 of 335) with videos related to

Sort By:
Pageof 34
Blood|February 19, 2025
Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMTCarmelo Gurnari, Marie Robin, Lionel Adès, et al.
The New England Journal of Medicine|December 12, 2023
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple MyelomaPieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, et al.
Eclinicalmedicine|January 22, 2026
HCT Frailty Scale (HCT-FS) for assessing frailty in adult candidates for allogeneic haematopoietic cell transplantation: an international prospective, observational cohort studyMaría Queralt Salas, Tommy Alfaro Moya, Ivan Pasic, et al.
Bone Marrow Transplantation|March 15, 2023
Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART eraAlberto Mussetti, Leyre Bento, Mariana Bastos-Oreiro, et al.
Nature Communications|September 20, 2023
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistanceCirino Botta, Cristina Perez, Marta Larrayoz, et al.
Future Oncology (London, England)|September 17, 2024
A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myelomaPieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, et al.
Therapeutic Advances in Medical Oncology|September 9, 2021
Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspectiveGehan Soosaipillai, Anjui Wu, Gino M Dettorre, et al.
Experimental Hematology & Oncology|September 1, 2020
Risk factors and outcome of COVID-19 in patients with hematological malignanciesJosé Luis Piñana, Rodrigo Martino, Irene García-García, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 20, 2014
Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphomaBaldeep Wirk, Timothy S Fenske, Mehdi Hamadani, et al.
American Journal of Hematology|August 19, 2024
Global characteristics and outcomes of autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma: A study of the worldwide network for blood and marrow transplantation (WBMT)Laurent Garderet, Luuk Gras, Linda Koster, et al.
Pageof 34